Mologic Strengthens Team with the Appointment of General Manager
News Oct 30, 2017
Mologic Ltd has announced the appointment of Mitch Brooker as General Manager. The new role has been created to drive Company growth, building on Mologic’s current reputation as a successful R&D provider, and increasing its full-service offering. Mitch will use his skills and experience to help lead these changes and take products from conception through to manufacture and commercialisation.
Mitch has 18 years of experience in medical devices, gained primarily in point-of-care and cancer diagnostics. Previously, he has worked at Surgipath Europe, where he transformed its distributor offering to include manufacturing capabilities, and Leica Biosystems, where he completed the integration of Surgipath Europe, following its acquisition. Mitch also led global projects to develop innovative monitoring products at Philips and conducted seven years of research at Huntingdon Life Sciences.
Mark Davis, Co-founder and CEO at Mologic commented: “Mologic is committed to growth and recognises the need to invest in the right people with the necessary experience, to enable this. We’re delighted to have Mitch join us as General Manager; his experience in driving the required cultural change as we enter a new growth phase will be invaluable and will help lead us in increasing our service offering to cover the full spectrum, from idea to commercial product.”
Mitch Brooker, General Manager at Mologic commented: “Mologic has a tremendous team who has enjoyed great success in contract research and product development. I look forward to helping the Company build on these successes and unlock its full commercial potential.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE